Login to Your Account

Epizyme Inks Epigenetics Deal With Celgene; $90M Up Front

By Trista Morrison
Staff Writer

Thursday, April 26, 2012

Epizyme Inc. is expected to announce early Thursday a broad epigenetics partnership with Celgene Corp. that brings the small biotech $90 million up front, at least $160 million in milestone payments per compound and double-digit royalties.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription